The small molecule drug, laquinimod, has failed to meet the primary endpoint in a Phase 2 study of patients with Huntington’s disease, a rare neurodegenerative disease. In May 2017 the same drug failed a Phase 3 trial in multiple sclerosis.
The drug is being developed by Teva Pharmaceutical Industries Ltd under licence from Active Biotech AB of Sweden. It is an immunomodulatory therapy that aims to prevent neurodegeneration and inflammation in the central nervous system.